Phase 2b study of inhaled RVT-1601 for chronic cough in idiopathic pulmonary fibrosis: SCENIC Trial: Multi-center, randomized, placebo-controlled study

This randomized, placebo-controlled, Phase 2b study evaluated the efficacy, safety, and optimal dosing of inhaled RVT-1601 in 108 adult patients with IPF and chronic cough. The primary endpoint was the change from baseline to Week 12 in 24-hour cough count, while secondary endpoints included change from baseline in cough severity and cough-specific quality of life. Cough outcomes were measured at home using the Vitalograph VitaloJAK recording device.